Partex.AI Welcomes FFI Ventures to Build the Industry's First End-to-End AI Partner for Life Sciences

One partner for the entire drug lifecycle. Precision AI at scale.
We are excited to announce that FFI Ventures has joined Partex.AI, marking a significant milestone in our mission to transform the future of life sciences through artificial intelligence.

This partnership brings together two organizations with a shared vision: enabling pharmaceutical, biotechnology, CRO, and medtech companies to accelerate innovation, improve decision-making, and deliver better outcomes for patients.

By combining FFI Ventures' deep expertise in medical affairs, regulatory affairs, pharmacovigilance, market access, and commercial strategy with Partex.AI's AI infrastructure, biomedical knowledge graph, drug discovery capabilities, and proprietary technology platforms—including Ontosight MetaD3 and Ontosight Asset42—we are creating the industry's first fully integrated, end-to-end AI partner supporting the entire therapy lifecycle, from discovery to patient outcomes.

A New Model for the Life Sciences Industry
For decades, life science organizations have relied on multiple specialized vendors across different stages of drug development. While each partner may excel in a particular function, fragmented workflows often lead to delays, duplicated effort, and the loss of valuable scientific context.

Together, Partex.AI and FFI Ventures offer a fundamentally different model: a single integrated partner combining AI technology, biomedical data, scientific expertise, and commercial execution to accelerate innovation across every stage of the drug lifecycle.

What This Means for Our Clients
Accelerating Innovation Through Precision AI

Organizations can transform research, clinical development, medical affairs, customer engagement, licensing, and commercialization using AI solutions that have demonstrated reductions of 35–83% in knowledge work while shortening critical processes by up to 86%.

Together, we offer:

- Advanced biomedical knowledge graphs and real-world evidence

- Ontosight MetaD3, delivering AI-powered discovery and development solutions

- Ontosight Asset42, serving as a unified intelligence ecosystem across the entire therapeutic asset lifecycle

- Asset Exchange, an AI-powered marketplace designed to unlock the value of therapeutic assets and optimize the licensing process

- ONERAY.AI, providing pharmaceutical, biotechnology, and medtech organizations with Precision AI to enable faster, compliant, and data-driven strategic decision-making

- In-house wet lab capabilities to rapidly validate hypotheses and profile molecules

Deep Scientific and Commercial Expertise
Our combined organization brings together experienced leaders and specialists across more than 40 therapy areas, supported by:

- More than 2.2 million patient records for real-world evidence analyses
- A biomedical knowledge graph comprising approximately 85 million nodes and 665 million unique relationships
- 186 granted patents and 321 patent applications
- Three oncology therapeutic assets advancing through the Partex.AI pipeline

Global Scale with Integrated Execution
The combined organization operates across Germany, Switzerland, the GCC, India, Singapore, and the United States, supported by:

- More than 200 professionals
- AI infrastructure powered by access to more than 1,000 NVIDIA DGX H100 GPUs

Looking Ahead
This partnership is about much more than combining capabilities. It brings together two teams that share a common belief: that Precision AI, combined with scientific excellence and deep industry expertise, will redefine how therapies are discovered, developed, and delivered.

By welcoming FFI Ventures into Partex.AI, we are strengthening our ability to support life science organizations across the complete therapy lifecycle with one integrated partner.

Together, we will continue pushing the boundaries of AI to accelerate innovation and create measurable value for our clients—and ultimately, for patients worldwide.

We are one team now. And we're just getting started.